Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds - Full Text View

Purpose

The main goal of this phase III clinical trial is to show safety and efficacy of Oleogel-S10 in the acceleration of wound healing of grade 2a burn wounds.

Condition	Intervention	Phase
Burns	Drug: Oleogel-S10 ointment Device: Octenilin® wound gel	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Burn Wounds

Resource links provided by NLM:

MedlinePlus related topics: Burns

U.S. FDA Resources

Further study details as provided by Birken AG:

Primary Outcome Measures:

Percentage of patients with earlier healing of the wound half treated with Oleogel-S10 compared to the wound half receiving standard of care [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: No ]
Photo-based evaluation by independent experts blinded to the treatment regime.

Secondary Outcome Measures:

Intra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 or treated with standard of care [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: No ]
Time from study start after burn accident until wound closure is achieved separately for wound halves treated with Oleogel-S10 vs. standard of care [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: No ]
Percentage of patients with wound closure at different time points [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: No ]
Percentage of wound epithelialization at different time points as assessed by the Investigator [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: No ]
Likert scale rating of efficacy (evaluated by both the Investigators and patients) [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: No ]
By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to grade the efficacy of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale
Cosmetic outcome after 3 and 12 months after burn accident, in relation to texture, redness, growth of hair and pigmentation, based on blinded photo evaluation [ Time Frame: 3 and 12 months ] [ Designated as safety issue: No ]
Likert scale rating of tolerance (evaluated by both the Investigators and patients) [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: Yes ]
By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to provide their opinion on the tolerance of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale
PK data: Systemic presence/concentration of betulin in blood plasma samples [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: Yes ]
Microbial colonization of the wound halves [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: Yes ]
Assessment of adverse events [ Time Frame: 2 to 3 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	60
Study Start Date:	August 2012
Estimated Study Completion Date:	July 2014
Estimated Primary Completion Date:	April 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Oleogel-S10 ointment Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.	Drug: Oleogel-S10 ointment Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing Device: Octenilin® wound gel Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing Other Name: Contains Octenidine
Octenilin® wound gel Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.	Drug: Oleogel-S10 ointment Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing Device: Octenilin® wound gel Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing Other Name: Contains Octenidine

Detailed Description:

Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in patients with skin lesions. Especially the results in the split-thickness skin graft donor site, which is regarded as an excellent model for any kind of superficial wounds in human skin, suggest that Oleogel-S10 should be efficacious and safe in treatment of grade 2a burns.

The present Phase III clinical trial in grade 2a burns is initiated in order to measure the wound healing progress applying objective methods, i.e., the time to healing and the grade of epithelialization of the wound.

In this study, grade 2a burn wounds are separated into two halves: Following wound cleaning and disinfection, wounds are separated into two wound halves. Randomly assigned, one wound half receives Oleogel-S10 ointment, the other wound half standard of care treatment.

Wound healing progress is documented by photos which are assessed by expert reviewers blinded to the treatment of the wound halves.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients at least 18 years old who have provided written informed consent.
Presenting with acute grade 2a burn wounds (as graded by an expert surgeon assisted by LDI or a multispectral imaging system) within 48 hours after injury.
Burn wound caused by fire burn, heat burn or scalding.
Burn patients with grade 2a burn wounds between 80 cm2 and less than 25% of their TBSA (alternatively, 2 comparable wounds with size more than 40 cm2 each and less than 12.5% of the TBSA each are allowed).
Patient is able to understand the Informed Consent Form provided and is prepared to comply with all study requirements, including the following: Visiting the trial site for wound dressing changes at least every second day (if patient is not hospitalized) and photo documentation until full wound closure or until the Investigator decides to change medication and/or treatment after day 21 after start of treatment
Willing to perform all necessary wound dressing changes at the trial site. Also the patient needs to agree to return to site for 3 and 12 months follow-up visits.
Women of childbearing potential must apply highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly (e.g., implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner))

Exclusion Criteria:

Suffering from chemical burns, or electrical burns or sunburns
Having already received treatment for their burn with silver sulfadiazine (obscures photographic wound evaluation).
Positive blood culture after the burn.
Diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerance or efficacy.
A skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
A history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.
Known multiple allergic disorders.
Taking, or have taken, any investigational drugs within 3 months prior to the screening visit.
Pregnant or breast feeding women are not allowed to participate in the study.
Inappropriate to participate in the study, for any reason, in the opinion of the Investigator.
Mental incapacity or language barriers precluding adequate understanding or co-operation or willingness to follow study procedures.
Previous participation in this study.
Employee at the investigational site, relative or spouse of the Investigator

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01657292

Contacts

Contact: Karl Schorn, Dr.

k.schorn@birken.eu

Locations

Germany
Unfallkrankenhaus Berlin	Recruiting
Berlin, Germany
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil	Recruiting
Bochum, Germany
Berufsgenossenschaftliche Kliniken Bergmannstrost, Halle	Recruiting
Halle, Germany
Universitätsklinikum Schleswig-Holstein	Recruiting
Lübeck, Germany
Sweden
Linköping University Hospital	Recruiting
Linköping, Sweden
University Hospital	Recruiting
Uppsala, Sweden
Switzerland
Centre Hospitalier Universitaire Vaudois	Recruiting
Lausanne, Switzerland
Universitätsspital Zürich	Recruiting
Zürich, Switzerland
United Kingdom
University Hospitals Birmingham NHS Foundation Trust	Recruiting
Birmingham, United Kingdom
Broomfield Hospital	Recruiting
Chelmsford, United Kingdom
Queen Victoria Hospital	Recruiting
East Grinstead, United Kingdom

Sponsors and Collaborators

Birken AG

Investigators

Principal Investigator:

Bernd Hartmann, Dr.

Trauma Hospital Berlin, Warener Str. 7, 12683 Berlin, Germany

More Information

No publications provided

Responsible Party:	Birken AG
ClinicalTrials.gov Identifier:	NCT01657292 History of Changes
Other Study ID Numbers:	BBW-11, 2012-000362-38
Study First Received:	July 29, 2012
Last Updated:	March 13, 2013
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices Sweden: Medical Products Agency Switzerland: Swissmedic United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Birken AG:

Wound healing
Burn wound
Superficial partial-thickness burn wound
Grade 2a burn wounds
Time to wound closure

Additional relevant MeSH terms:

Burns
Wounds and Injuries

ClinicalTrials.gov processed this record on May 23, 2013